• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Noveome Biotherapeutics inks licensing deal for SipNose drug delivery device

June 1, 2021 By Sean Whooley

Noveome SipNoseNoveome Biotherapeutics announced that it entered a commercial license agreement to use SipNose’s proprietary drug delivery device.

Yokneam, Israel–based SipNose develops its intranasal Cribriform Targeted Device (CT6), which, under the agreement, was licensed to Noveome to deliver the Pittsburgh-based company’s ST266 biologic to the central nervous systems, according to a news release.

CT6 allows aerosolized drug delivery to the cribriform area in the upper area of the nasal cavity, SipNose said, offering highly reproducible dosing, high absorption of the drug and the potential for higher efficacy combined with an improved user experience.

Noveome produces ST266 by collecting proteins and other factors secreted by a novel population of cells generated by a proprietary method of culturing amnion-derived epithelial cells collected from full-term placentas that are normally discarded following birth.

The secretome holds physiologic levels of multiple growth factors and cytokines while demonstrating the stimulation of anti-inflammatory and neuroprotective responses in preclinical studies. Noveome said it continues to evaluate ST266 in central nervous system conditions, gastrointestinal conditions and cytokine storm associated with COVID-19 infection.

Noveome has submitted a drug master file with the FDA to support all ST266 investigational new drug applications, while the company says the ST266 platform biologic enables a scalable manufacturing process for all of those indications.

SipNose and Noveome have collaborated since 2015, with the licensing agreement covering the intranasal delivery of ST266 for treating ophthalmological conditions and brain-related conditions. Along with the license terms, Noveome and SipNose agreed to terms for a supply agreement set to be finalized before initiating Phase 3 trials.

Noveome founder & chairman William J. Golden said in the release that the companies have a great working relationship, while Noveome recently closed enrollment for and completed the treatment phase of its Phase 1 study using the SipNose device in glaucoma-suspect patients.

“This agreement represents a breakthrough in the area of non-invasive direct nose to brain delivery resulting from our intensive collaboration over the past 5 years,” SipNose co-founder & CEO Dr. Iris Shichor said in the release. “We are proud to collaborate with Noveome and to promote the use of their biologic ST266 with our proprietary delivery technology for the benefit of patients suffering from ophthalmological and neurological conditions.”

Filed Under: Business/Financial News, Clinical Trials, Drug-Device Combinations, Featured, Neurological, Optical/Ophthalmic, Otolaryngology Ear, Nose & Throat Tagged With: Noveome Biotherapeutics, SipNose

IN CASE YOU MISSED IT

  • Breakthrough T1D, Mattel debut Barbie doll with type 1 diabetes
  • Medtronic Diabetes names CFO with consumer experience ahead of separation
  • Diabeloop launches insulin delivery algorithm in Germany
  • GlucoModicum has positive data for needle-free CGM
  • Lifecare takes next steps in CGM implant development

About Sean Whooley

Sean Whooley is an associate editor who mainly produces work for MassDevice, Medical Design & Outsourcing and Drug Delivery Business News. He received a bachelor's degree in multiplatform journalism from the University of Maryland, College Park. You can connect with him on LinkedIn or email him at swhooley@wtwhmedia.com.

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS